ACET Adicet Bio Inc

Price (delayed)

$14.12

Market cap

$565.23M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.34

Enterprise value

$326.98M

Adicet Bio, Inc. is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet is advancing a pipeline of 'off-the-shelf' gamma delta ...

Highlights
The quick ratio has soared by 56% YoY but it has decreased by 41% from the previous quarter
The company's net income fell by 32% QoQ but it rose by 15% YoY
ACET's EPS is down by 20% since the previous quarter
The gross profit has declined by 12% since the previous quarter

Key stats

What are the main financial stats of ACET
Market
Shares outstanding
40.03M
Market cap
$565.23M
Enterprise value
$326.98M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.93
Price to sales (P/S)
16.7
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.65
Earnings
Revenue
$33.89M
EBIT
-$47.64M
EBITDA
-$43.67M
Free cash flow
-$49.47M
Per share
EPS
-$1.34
Free cash flow per share
-$1.23
Book value per share
$7.33
Revenue per share
$0.85
TBVPS
$7.75
Balance sheet
Total assets
$329.9M
Total liabilities
$36.64M
Debt
$22.39M
Equity
$293.27M
Working capital
$247.69M
Liquidity
Debt to equity
0.08
Current ratio
16.1
Quick ratio
15.89
Net debt/EBITDA
5.46
Margins
EBITDA margin
-128.9%
Gross margin
100%
Net margin
-140.9%
Operating margin
-139.4%
Efficiency
Return on assets
-15.1%
Return on equity
-17%
Return on invested capital
-96.8%
Return on capital employed
-15.2%
Return on sales
-140.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ACET stock price

How has the Adicet Bio stock price performed over time
Intraday
0.79%
1 week
-14.84%
1 month
-22.37%
1 year
109.81%
YTD
-19.27%
QTD
-3.29%

Financial performance

How have Adicet Bio's revenue and profit performed over time
Revenue
$33.89M
Gross profit
$33.89M
Operating income
-$47.25M
Net income
-$47.75M
Gross margin
100%
Net margin
-140.9%
Adicet Bio's operating margin has soared by 77% YoY but it has plunged by 53% from the previous quarter
Adicet Bio's net margin has surged by 77% YoY but it has shrunk by 51% QoQ
ACET's operating income is down by 34% from the previous quarter but it is up by 14% YoY
The company's net income fell by 32% QoQ but it rose by 15% YoY

Growth

What is Adicet Bio's growth rate over time

Valuation

What is Adicet Bio stock price valuation
P/E
N/A
P/B
1.93
P/S
16.7
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.65
ACET's EPS is down by 20% since the previous quarter
Adicet Bio's equity has increased by 28% YoY but it has decreased by 6% QoQ
The P/S is 44% below the last 4 quarters average of 29.8
Adicet Bio's revenue has decreased by 12% QoQ

Efficiency

How efficient is Adicet Bio business performance
ACET's return on sales has surged by 77% year-on-year but it has dropped by 51% since the previous quarter
ACET's ROE is up by 47% YoY but it is down by 25% QoQ
Adicet Bio's ROIC has increased by 47% YoY but it has decreased by 19% from the previous quarter
Adicet Bio's return on assets has increased by 42% YoY but it has decreased by 26% QoQ

Dividends

What is ACET's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ACET.

Financial health

How did Adicet Bio financials performed over time
ACET's current ratio has surged by 56% year-on-year but it is down by 41% since the previous quarter
The quick ratio has soared by 56% YoY but it has decreased by 41% from the previous quarter
Adicet Bio's debt is 92% lower than its equity
Adicet Bio's equity has increased by 28% YoY but it has decreased by 6% QoQ
ACET's debt to equity is up by 14% QoQ but it is down by 11% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.